Besides the MC4R‐targeted treatment, glucagon‐like peptide‐1 (GLP‐1) receptor agonists (such as semaglutide) in combination with lifestyle interventions can reduce body weight in individuals with overweight or obesity.56 Here, MC4R is linked to obesity disorder.